Tag
SHARP registry data reveal that biologic therapies improve clinical outcomes equally in severe asthma patients irrespective of smoking status, challenging prevailing prescribing hesitancy and advocating inclusive treatment approaches.
This review summarizes the progression risk from mild-to-moderate to severe asthma based on the NORDSTAR cohort and integrates emerging evidence on biologic therapies that improve severe asthma outcomes across diverse patient profiles.
A recent MAIC study comparing mepolizumab and dupilumab in eosinophilic COPD patients found no significant difference between the treatments in reducing exacerbations or improving quality of life.
This review synthesizes current evidence on adalimumab, secukinumab, and bimekizumab for moderate-to-severe hidradenitis suppurativa, emphasizing clinical efficacy, safety, mechanistic insights, and cost-effectiveness across diverse health
This review synthesizes the 52-week pooled results from two Phase 3 trials, detailing the pharmacokinetics, safety, and biomarker responses of secukinumab in moderate-to-severe hidradenitis suppurativa.
The FDA has approved depemokimab (Exdensur), the first long-acting biologic for severe eosinophilic asthma. Requiring only two doses per year, it significantly reduces exacerbations and hospitalizations, offering a transformative shift in t
The multicentre open-label SHINE-1 phase 2 trial found that mirikizumab produced clinically meaningful induction and maintenance responses in children with moderate-to-severe ulcerative colitis, with an acceptable safety profile over 52 wee
A nationwide retrospective cohort (36,129 patients) found antibiotic use before or during biologic treatment for psoriasis was associated with higher risk of discontinuation or switch; multiple dispensations carried larger risk, suggesting
A phase 2 randomized, placebo‑controlled trial found sonelokimab — a nanobody that inhibits IL‑17A and IL‑17F — produced significant improvements in joint and skin outcomes in active psoriatic arthritis versus placebo, with an acceptable sh
The LOVE‑CD phase 4 cohort shows vedolizumab yields higher sustained clinical and endoscopic remission and fewer serious adverse events when given early in Crohn’s disease versus later-stage, previously biologic‑exposed disease.
An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑
This living systematic review and network meta-analysis evaluates efficacy, safety, and tolerability of medical treatments for moderate to severe hidradenitis suppurativa, highlighting top-performing agents and informing clinical decision-m
PANLAR’s 2025 evidence-based recommendations for non-systemic polyarticular JIA emphasize early treat-to-target care using methotrexate, targeted escalation to biologics when needed, region-sensitive alternatives (leflunomide, triple nbDMAR
Real-world analysis of 3318 US patients with CRSwNP treated with dupilumab demonstrated high persistence and adherence at 12 months, with significant rates of treatment reinitiation after discontinuation, underscoring dupilumab’s sust
